Somite Therapeutics Partners with OmniaBio to Advance DMD Cell Therapy

• Somite Therapeutics partners with OmniaBio to advance cell therapy for Duchenne muscular dystrophy (DMD).

• Collaboration will focus on developing and manufacturing Somite’s flagship DMD program, SMT-M01.

Somite Therapeutics, a tech-bio company specialising in AI-driven cell replacement therapies, has announced a collaboration with OmniaBio Inc., a CDMO focused on cell and gene therapies, to produce its flagship program for Duchenne muscular dystrophy (DMD). The partnership centres on the development and manufacturing of SMT-M01, Somite’s cell therapy aimed at addressing the severe genetic disorder.

DMD is a rare disease that leads to progressive muscle degeneration, with no current cure. The collaboration will leverage OmniaBio’s expertise in induced pluripotent stem cell (iPSC) technology to develop a treatment designed to restore muscle function and slow the disease’s progression. OmniaBio will manage process optimisation, cell banking, and production to support the clinical development of SMT-M01.

The partnership is expected to advance Somite’s cell therapy into phase 1/2 clinical trials within 18-24 months. Dr. Micha Breakstone, Founder and CEO of Somite, noted, “This collaboration is a great step forward, and the data generated will drive advancements in our therapeutic approach.”

Mitchel Sivilotti, President and CEO of OmniaBio, highlighted the potential of the collaboration: “We are thrilled to provide our expertise in iPSC technology and AI-driven manufacturing to accelerate clinical translation for this vital program.”